The FDA last week approved AbbVie’s Rinvoq for the treatment of ulcerative colitis, the JAK inhibitor’s third label expansion in the past four months. Rinvoq was first approved in rheumatoid arthritis in 2019. For the treatment of the disease, the JAK inhibitor holds covered or better status for 96% of all insured lives. 36% of all covered lives have preferred access to Rinvoq, largely with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 3/23/22